©Author(s) (or their employer(s)) 2026.
World J Gastroenterol. Mar 14, 2026; 32(10): 115130
Published online Mar 14, 2026. doi: 10.3748/wjg.v32.i10.115130
Published online Mar 14, 2026. doi: 10.3748/wjg.v32.i10.115130
Table 1 Clinical backgrounds of enrolled patients and histopathological features of primary colorectal cancer and liver metastases, n (%)/median (minimum-maximum)
| Parameter | Stage I-III (n = 44) | Stage IV (n = 55) | P value | ||
| Age at the diagnosis (years) | 64 (46-73) | 62 (29-78) | 0.31 | ||
| Gender | Male | 29 (65.9) | 34 (61.8) | 0.67 | |
| Female | 15 (34.1) | 21 (38.2) | |||
| Primary tumor | |||||
| Location | Right colon | 8 (18.2) | 12 (21.8) | 0.65 | |
| Left colon | 36 (81.8) | 43 (78.2) | |||
| Size (cm) | 3.5 (0.8-8.3) | 4.3 (1.0-7.5) | |||
| Pathologic T stage | T1 | 1 (2.3) | 0 (0.0) | 0.25 | |
| T2 | 6 (13.6) | 1 (1.8) | |||
| T3 | 35 (79.5) | 48 (87.3) | |||
| T4 | 2 (4.5) | 6 (10.9) | |||
| Histological type | Not otherwise specified | 39 (88.6) | 51 (92.7) | ||
| Mucinous | 4 (9.1) | 2 (3.6) | |||
| Other | 1 (2.3) | 2 (3.6) | |||
| Pathologic N stage | N0 | 13 (29.5) | 13 (23.6) | 0.51 | |
| N1 | 16 (36.4) | 22 (40.0) | |||
| N2 | 15 (34.1) | 20 (36.4) | |||
| American Joint Committee on Cancer 8th staging | Stage I | 1 (2.3) | |||
| Stage II | 12 (27.3) | ||||
| Stage III | 31 (70.4) | ||||
| Stage IV | 55 (100) | ||||
| Grade | 1 | 14 (31.8) | 12 (21.8) | 0.77 | |
| 2 | 26 (59.1) | 37 (67.3) | |||
| 3 | 4 (9.1) | 6 (10.9) | |||
| KRAS status | Mutated | 11 (25.0) | 20 (36.4) | 0.26 | |
| Wild-type | 25 (56.8) | 27 (49.1) | |||
| Not tested | 8 (18.2) | 8 (14.5) | |||
| BRAF status | Mutated | 1 (2.3) | 0 (0.0) | 0.27 | |
| Wild-type | 35 (79.5) | 44 (80.0) | |||
| Not tested | 8 (18.2) | 11 (20.0) | |||
| Microsatellite instability status | High | 1 (2.3) | 1 (1.8) | 0.90 | |
| Low | 35 (79.5) | 42 (76.4) | |||
| Not tested | 8 (2.3) | 12 (21.8) | |||
| CEA ng/mL | 8.9 (0.8-1649.0) | 6.8 (1.0-945.0) | 0.90 | ||
| CEA | < 5 ng/mL | 13 (46.4) | 18 (46.2) | ||
| > 5 ng/mL | 15 (53.6) | 21 (53.8) | 0.98 | ||
| Number of examined lymph nodes | 11 (0-43) | 13 (1-34) | 0.38 | ||
| Lymph node ratio | 0.13 (0-0.32) | 0.22 (0-0.57) | 0.14 | ||
| Liver metastases | |||||
| Number | 1 (1-7) | 2 (1-24) | 0.08 | ||
| Size (cm) | 2.7 (0.6-7.1) | 2.0 (0.4-26.0) | 0.02 | ||
| Grade | 1 | 18 (42.9) | 21 (39.6) | 0.75 | |
| 2 | 24 (57.1) | 32 (60.4) | |||
| Metastasis resection | R0 | 29 (69.0) | 40 (76.9) | 0.39 | |
| R status | R1 | 13 (31.0) | 12 (23.1) | ||
| Chemotherapy ± targeted therapy | CHT alone | 30 (68.2) | 28 (50.9) | 0.07 | |
| CHT + anti-vascular endothelial growth factor | 4 (9.1) | 11 (20.0) | |||
| CHT + anti-epidermal growth factor receptor | 5 (11.4) | 9 (16.4) | |||
| No treatment | 2 (4.5) | 4 (7.3) | |||
| Not known | 3 (6.8) | 3 (5.4) | |||
| Chemotherapy regimens | FOLFOX | 16 (36.4) | 31 (56.4) | 0.05 | |
| Dle Gramont | 9 (20.5) | 7 (12.7) | |||
| FOLFIRI | 2 (4.5) | 4 (7.3) | |||
| Others | 12 (27.3) | 6 (10.9) | |||
- Citation: Ye WJ, Ali E, Pavlov S, Červenková L, Ambrozkiewicz F, Vyčítal O, Hošek P, Zitrický F, Daum O, Liška V, Hemminki K, Trailin A. Distribution and prognostic value of macrophages in colorectal cancer and adjacent mucosa in patient stages I-III vs IV. World J Gastroenterol 2026; 32(10): 115130
- URL: https://www.wjgnet.com/1007-9327/full/v32/i10/115130.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i10.115130